Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 26;16(1):6889.
doi: 10.1038/s41467-025-62201-2.

Integrated multiomics of pressure overload in the human heart prioritizes targets relevant to heart failure

Affiliations

Integrated multiomics of pressure overload in the human heart prioritizes targets relevant to heart failure

Brian R Lindman et al. Nat Commun. .

Abstract

Pressure overload initiates a series of alterations in the human heart that predate macroscopic organ-level remodeling and downstream heart failure. We study aortic stenosis through integrated proteomic, tissue transcriptomic, and genetic methods to prioritize targets causal in human heart failure. First, we identify the circulating proteome of cardiac remodeling in aortic stenosis, specifying known and previously-unknown mediators of fibrosis, hypertrophy, and oxidative stress, several associated with interstitial fibrosis in a separate cohort (N = 145). These signatures are strongly related to clinical outcomes in aortic stenosis (N = 802) and in broader at-risk populations in the UK Biobank (N = 36,668). We next map this remodeling proteome to myocardial transcription in patients with and without aortic stenosis through single-nuclear transcriptomics, observing broad differential expression of genes encoding this remodeling proteome, featuring fibrosis pathways and metabolic-inflammatory signaling. Finally, integrating our circulating and tissue-specific results with modern genetic approaches, we implicate several targets as causal in heart failure.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Lindman is supported by R01HL164526 and R01AG073633 from the NIH, has received investigator-initiated research grant funding and consulted for Edwards Lifesciences, and consulted for Astra Zeneca, Medtronic, Kardigan, and Anteris. Dr. Perry has patents pending for proteomic signatures of fitness, lung, and liver disease. Dr. Amancherla is supported by an American Heart Association (AHA) Career Development Award (#929347), the NIH (K23HL166960), the Red Gates Foundation, and an International Society for Heart and Lung Transplantation Enduring Hearts Transplant Longevity Award. Dr. Amancherla has an institutional disclosure filed for spatial RNA biomarkers of transplant rejection and allograft health. Dr. Gerszten is supported by a Leducq foundation grant (21CVD01). Dr. Nayor supported by R01HL156975 and R01HL131029 from the NIH. Dr. Gillam is an advisor Medtronic, Philips, and Egnite and oversees core lab contracts with Edwards Lifesciences, Medtronic, and Abbott (no direct compensation). Dr Dweck is supported by the British Heart Foundation (FS/SCRF/21/32010) and is the recipient of the Sir Jules Thorn Award for Biomedical Research 2015 (15/JTA). Dr. Das is a founder of Thryv Therapeutics and Switch Therapeutics with equity in both, and has research grants from Bristol Myers Squibb, National Institutes of Health (R35HL 105807). Dr. Gupta is supported by R01HL153607, R01HL154153-03, R01HL148661, R01AG034962, and R01HL145293 from the NIH and is patent holder (#11,079,394) for detection of angiopoietin-2 and thrombospondin-2 for the diagnosis of acute heart failure. Dr. Miller is supported by the Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. Dr. Tucker is supported by the NIH R01-HL170051. Dr. Gamazon is a consultant for Thryv Therapeutics, and is a co-inventor on pending patents or disclosures on cardiovascular diseases and phenotypes, and metabolic health, use of RNAs as therapeutics and diagnostic biomarkers in disease, and methods in metabolomics. Dr. Shah is supported by grants from the National Institutes of Health. Dr. Shah has equity ownership in and is a consultant for Thryv Therapeutics. Dr. Shah is a co-inventor on pending patents or disclosures on molecular biomarkers of fitness, lung disease, cardiovascular diseases and phenotypes, and metabolic health, use of RNAs (including spatial) as therapeutics and diagnostic biomarkers in disease, and methods in metabolomics. Dr. Elmariah is supported by institutional research grants from the NIH (5R01HL151838), the Patient-Centered Outcomes Research Institute, Edwards Lifesciences, Medtronic, and Abbott. Dr. Elmariah is a consultant for Edwards Lifesciences and holds equity and is co-founder of Prospect Health. The remaining authors have no relevant disclosures.

Figures

Fig. 1
Fig. 1. Integration of the circulating proteome and tissue sequencing to prioritize targets of cardiac remodeling.
Overview of our study design. AS aortic stenosis, CMR cardiac magnetic resonance imaging. PC1 = LV Volumes; PC2 = LV Systolic function; PC3 = LV Diastolic function.
Fig. 2
Fig. 2. Principal component analysis generates 3 phenotypic components of cardiac remodeling.
We used principal component analysis (PCA) on 12 echocardiographic measures of cardiac structure and function in the discovery cohort derivation sample (N = 519) and identified 3 composite axes of remodeling that accounted for 65% of the variance. A Loadings for each of the 3 principal components. B Heatmap demonstrating individual level data on the 12 echocardiographic measures and participants’ corresponding principal component value. Source data are provided as a Source Data file. PC principal component, LV left ventricular, RWT relative wall thickness, SVI stroke volume index, AV aortic valve, LVEF left ventricular ejection fraction, LV DTI LV tissue Doppler S lateral annulus, LVESDI left ventricular end-systolic diameter index, LVEDDI left ventricular end-diastolic diameter index, LVESVI left ventricular end-systolic volume index, LVEDVI left ventricular end-diastolic volume index, LVMi left ventricular mass index, LA Vol left atrial volume.
Fig. 3
Fig. 3. Validation of proteomic markers of remodeling in a CMR-based cohort.
We examined the relations of the 270 proteins related to any echocardiographic component of remodeling (Supplemental Fig. 2) with cardiac magnetic resonance imaging (CMR) based measures of remodeling and fibrosis. For visualization, proteins related to any CMR measure with an FDR < 0.1 (Benjamini–Hochberg) are presented. Source data are provided as a Source Data file. ECV extracellular volume, LVMI left ventricular mass index, LAVI left atrial volume index, DT deceleration time, EF left ventricular ejection fraction. * FDR < 0.1; ** FDR < 0.05.
Fig. 4
Fig. 4. Proteomic signatures of remodeling are related to clinical outcomes in both an AS population and a general “at-risk” population.
A Forest plot of Cox regression results from the discovery cohort relating the proteomic scores to post-TAVI all-cause mortality. Derivation sample N = 500 in unadjusted models. Validation sample N = 302 in unadjusted models. B Forest plot of Cox regression results from the UK Biobank (N = 36,668 in unadjusted models) relating proteomic scores of remodeling to all-cause mortality and incident heart failure. Source data are provided as a Source Data file.
Fig. 5
Fig. 5. Proteo-transcriptional architecture of human aortic stenosis.
UMAP of cell types (A) and condition (B) defined by single-nuclear RNA-sequencing (114,288 nuclei across 7 broad clusters). C Cell composition by condition identifies a significant increase in endothelial cells in AS hearts; *** represents significance. D Heatmap representing the differentially expressed genes associated with remodeling across pseudobulk and cell-specific analyses. Numbers adjacent to the cell type label represent the total number of significant genes, inclusive of those which overlap across comparisons. E Select terms from Gene Ontology analysis of differentially expressed genes associated with remodeling, which highlight cell type-specific pro-angiogenic and pro-inflammatory processes. Full tabular results for all analyses are available in Supplementary Data 9. F Quantile-quantile plot showing the association of genetically determined circulating protein expression with HF. A leftward shift from the gray line shows departure from the null (standard uniform) distribution. The red dashed line denotes P<0.05. The protein IL15RA is shown twice as it is tagged by 2 SOMAmers, each of which shows an association with HF. G Quantile-quantile plot showing the association of genetically determined gene expression in the left ventricle with HF. A leftward shift from the gray line shows departure from the null (standard uniform) distribution. The red dashed line denotes P<0.05. Note MIF, HEXIM1, and ANXA4 also show P<0.05 in the association between the genetic component of the respective protein expression and HF. Source data are provided as a Source Data file.

References

    1. Chin, C. W. L. et al. Myocardial fibrosis and cardiac decompensation in aortic stenosis. JACC Cardiovasc. Imaging10, 1320–1333 (2017). - PMC - PubMed
    1. Treibel, T. A., Badiani, S., Lloyd, G. & Moon, J. C. Multimodality imaging markers of adverse myocardial remodeling in aortic stenosis. JACC Cardiovasc. Imaging12, 1532–1548 (2019). - PubMed
    1. Mahmod, M. et al. Histological evidence for impaired myocardial perfusion reserve in severe aortic stenosis. JACC Cardiovasc. Imaging12, 2276–2278 (2019). - PubMed
    1. Singh, A. et al. Determinants of exercise capacity and myocardial perfusion reserve in asymptomatic patients with aortic stenosis. JACC Cardiovasc. Imaging13, 178–180 (2020). - PubMed
    1. Gonzales, H. et al. Left ventricular hypertrophy and clinical outcomes over 5 years after TAVR: an analysis of the PARTNER trials and registries. JACC Cardiovasc. Inter.13, 1329–1339 (2020). - PubMed

MeSH terms

LinkOut - more resources